tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ACRS Stock Latest News

Aclaris Therapeutics: Promising Pipeline and Strategic Advancements Drive Buy Rating
RatingsAclaris Therapeutics: Promising Pipeline and Strategic Advancements Drive Buy Rating
1d ago
ACRS
Aclaris Therapeutics Hosts R&D Day for Innovations
PremiumCompany Announcements
Aclaris Therapeutics Hosts R&D Day for Innovations
7d ago
8K
ACRS
Aclaris Therapeutics to host R&D Day on October 14
PremiumThe Fly
Aclaris Therapeutics to host R&D Day on October 14
21d ago
ACRS
Promising Phase 2a Results and Strategic Expansion Drive Buy Rating for Aclaris Therapeutics
PremiumRatings
Promising Phase 2a Results and Strategic Expansion Drive Buy Rating for Aclaris Therapeutics
2M ago
ACRS
Aclaris Therapeutics Reports Q2 2025 Results and Updates
PremiumCompany Announcements
Aclaris Therapeutics Reports Q2 2025 Results and Updates
2M ago
ACRS
Aclaris Therapeutics reports Q2 EPS (13c), consensus (13c)
PremiumThe FlyAclaris Therapeutics reports Q2 EPS (13c), consensus (13c)
3M ago
ACRS
Positive Outlook for Aclaris Therapeutics Driven by Promising Trial Results and Pipeline Advancements
Premium
Ratings
Positive Outlook for Aclaris Therapeutics Driven by Promising Trial Results and Pipeline Advancements
3M ago
ACRS
Closing Bell Movers: Qorvo, Starbucks jump after quarterly reports
Premium
The Fly
Closing Bell Movers: Qorvo, Starbucks jump after quarterly reports
3M ago
LC
CAR
Aclaris announces ATI-2138 trial meets primary, secondary endpoints
PremiumThe Fly
Aclaris announces ATI-2138 trial meets primary, secondary endpoints
3M ago
ACRS
Aclaris Therapeutics Announces Positive Phase 2a Trial Results
PremiumCompany Announcements
Aclaris Therapeutics Announces Positive Phase 2a Trial Results
3M ago
8K
ACRS
Aclaris Therapeutics CSO Joe Monahan to retire, Roland Kolbeck to succeed
PremiumThe Fly
Aclaris Therapeutics CSO Joe Monahan to retire, Roland Kolbeck to succeed
3M ago
ACRS
Aclaris Therapeutics assumed with an Overweight at Piper Sandler
PremiumThe Fly
Aclaris Therapeutics assumed with an Overweight at Piper Sandler
3M ago
ACRS
Aclaris Therapeutics Highlights Clinical Pipeline and Outlook
PremiumCompany AnnouncementsAclaris Therapeutics Highlights Clinical Pipeline and Outlook
4M ago
8K
ACRS
Aclaris Therapeutics: Promising Pipeline and Strategic Trials Justify Buy Rating
Premium
Ratings
Aclaris Therapeutics: Promising Pipeline and Strategic Trials Justify Buy Rating
4M ago
ACRS
Aclaris Therapeutics initiates Phase 1a/1b program for ATI-052
Premium
The Fly
Aclaris Therapeutics initiates Phase 1a/1b program for ATI-052
4M ago
ACRS
Aclaris Therapeutics: Promising Pipeline and Strategic Advancements Support Buy Rating
PremiumRatings
Aclaris Therapeutics: Promising Pipeline and Strategic Advancements Support Buy Rating
4M ago
ACRS
Aclaris Therapeutics Approves 2025 Equity Incentive Plan
PremiumCompany Announcements
Aclaris Therapeutics Approves 2025 Equity Incentive Plan
5M ago
8K
ACRS
Aclaris Therapeutics initiates Phase 2 trial of bosakitug
PremiumThe Fly
Aclaris Therapeutics initiates Phase 2 trial of bosakitug
5M ago
ACRS
Optimistic Buy Rating for Aclaris Therapeutics Driven by Promising Dermatology Pipeline Developments
PremiumRatings
Optimistic Buy Rating for Aclaris Therapeutics Driven by Promising Dermatology Pipeline Developments
5M ago
ACRS
Wedbush bullish on Aclaris Therapeutics, initiates with an Outperform
PremiumThe FlyWedbush bullish on Aclaris Therapeutics, initiates with an Outperform
5M ago
ACRS
Aclaris Therapeutics initiated with an Outperform at Wedbush
Premium
The Fly
Aclaris Therapeutics initiated with an Outperform at Wedbush
5M ago
ACRS
Aclaris Therapeutics price target lowered to $16 from $20 at H.C. Wainwright
Premium
The Fly
Aclaris Therapeutics price target lowered to $16 from $20 at H.C. Wainwright
5M ago
ACRS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >